CSIMarket Company Name, Ticker, Competitors, else..
 

Genenta Science S p a   (NASDAQ: GNTA)

Genenta Science S P A 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

GNTA Sales vs. its Competitors Q4 2025


Comparing the current results to its competitors, Genenta Science S P A reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.87 %, recorded in the same quarter.

• List of GNTA Competitors





Revenue Growth Comparisons




Net Income Comparison

Genenta Science S p a , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 28.31 %

<<  GNTA Stock Performance Comparisons


Genenta Science S P A 's Comment on Competition and Industry Peers


The pharmaceutical industry faces competitive challenges influenced by Most Favored Nation (MFN) pricing initiatives, which affect drug prices in the United States and indirectly impact companies with competing products. Companies must also comply with diverse regulatory requirements outside the U.S. to market medicinal products. To protect proprietary know-how and maintain competitive positions, companies utilize patents, trade secrets, confidentiality agreements, and legal mechanisms. However, patent protection may be incomplete, and trade secrets can be compromised or independently discovered by competitors.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Genenta Science S p a




Tectonic Therapeutic Inc
Share Performance



-4.02%
Over The Past 5 Days
Tectonic Therapeutic Inc
Profile

Tectonic Therapeutic, Inc. develops therapeutic proteins and antibodies that target G protein-coupled receptors (GPCRs).

More about Tectonic Therapeutic Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 520.752 mill. $ - mill. $ -85.787 mill.


Solid Biosciences Inc
Share Performance



-2.59%
Over The Past 5 Days
Solid Biosciences Inc
Profile

Solid Biosciences Inc is a biotechnology company focused on developing gene therapies for individuals with Duchenne muscular dystrophy (DMD).

More about Solid Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,269.490 mill. $ - mill. $ -207.099 mill.


Sangamo Therapeutics Inc
Share Performance



-64.76%
30 Days
Sangamo Therapeutics Inc
Profile

Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients' lives.

More about Sangamo Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 28.832 mill. $ 34.557 mill. $ -123.330 mill.


Sana Biotechnology Inc
Share Performance



-11.43%
30 Days
Sana Biotechnology Inc
Profile

Sana Biotechnology Inc operates as a biotechnology company that focuses on developing and commercializing cellular therapies for various diseases. Their business model involves leveraging innovative technologies and collaborations with clinical and industry partners to develop advanced medical treatments.

More about Sana Biotechnology Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 950.569 mill. $ - mill. $ -211.822 mill.


Regenxbio Inc
Share Performance



-26.74%
30 Days
Regenxbio Inc
Profile

Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.

More about Regenxbio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 429.960 mill. $ 174.482 mill. $ -196.432 mill.

43 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Genenta Science S p a’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Genenta Science S p a versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.